GENCURIX, a molecular diagnostics company specializing in cancer, announced on the 2nd that it will expand the provision of breast cancer prognosis diagnostic tests to secondary general hospitals following its provision to advanced general hospitals.
GENCURIX received approval from the National Evidence-based Healthcare Collaborating Agency (NECA) for the additional use of breast cancer prognosis diagnostic tests at 15 secondary general hospitals as implementation institutions. This follows an amendment to regulations regarding innovative medical technologies, allowing the use of gene tests in non-certified institutions.
The breast cancer prognosis diagnostic test "Genswell BCT" is the first test developed for Asians. It uniquely obtained the "manufacturing and product approval" from the Ministry of Food and Drug Safety in South Korea. Genswell BCT is also applicable for health insurance coverage, thereby reducing the financial burden on patients.
GENCURIX has announced research results demonstrating its superiority through comparative studies with U.S. breast cancer prognosis diagnostic products at the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO). Last year, despite the impact of strikes in the medical sector, the number of hospitals adopting Genswell BCT continued to increase.
Choi Chung-yeol, head of diagnostic medicine at GENCURIX, noted, "Genswell BCT has established itself as a domestic product that replaces the U.S. breast cancer prognosis diagnostic products that have dominated the domestic market," adding, "This year, we will accelerate global market expansion through collaboration with various Asian medical institutions, including those in China and Japan."